Skip to main content
. Author manuscript; available in PMC: 2019 May 20.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Aug 18;18(12):803–813.e7. doi: 10.1016/j.clml.2018.08.007

Figure 2.

Figure 2

Reduction in Lymph Nodes* (A) and Splenic Enlargement† (B) (Primary Analysis)

*Sum of the products of multiple lymph nodes (as evaluated by computed tomography scans) or the longest diameter of one target lymph node. †Patients who experienced resolution of splenic enlargement by IRC are considered to have 100% reduction.

Abbreviations: IRC = independent review committee; NE = not evaluable; PD = progressive disease; PR = partial response; PR-L = PR with lymphocytosis; SD = stable disease.